<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01228331</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000686545</org_study_id>
    <secondary_id>2009-012758-18</secondary_id>
    <nct_id>NCT01228331</nct_id>
  </id_info>
  <brief_title>Clofarabine or High-Dose Cytarabine and Pegaspargase in Children With ALL</brief_title>
  <official_title>A Randomized Multi-Center Treatment Study (COALL 08-09) to Improve the Survival of Children With Acute Lymphoblastic Leukemia on Behalf of the German Society of Pediatric Hematology and Oncology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer&#xD;
      cells, either by killing the cells or by stopping them from dividing. Giving more than once&#xD;
      drug (combination chemotherapy) may kill more cancer cells. Radiation therapy uses&#xD;
      high-energy x-rays to kill cancer cells. It is not yet known whether giving clofarabine or&#xD;
      high-dose cytarabine, pegaspargase, and combination chemotherapy followed by daunorubicin&#xD;
      hydrochloride or doxorubicin hydrochloride is more effective in treating young patients with&#xD;
      acute lymphoblastic leukemia.&#xD;
&#xD;
      PURPOSE: This randomized phase II/III trial is studying the side effects of giving&#xD;
      clofarabine compared with giving high-dose cytarabine, pegaspargase, and combination&#xD;
      chemotherapy followed by daunorubicin hydrochloride or doxorubicin hydrochloride and to see&#xD;
      how well it works in treating young patients with T-cell acute lymphoblastic leukemia or&#xD;
      precursor B-cell acute lymphoblastic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To investigate the safety and efficacy of clofarabine combined with pegaspargase in&#xD;
           patients with high-risk acute lymphoblastic leukemia during the first phase of the&#xD;
           study. (Phase II)&#xD;
&#xD;
        -  To investigate, in terms of minimal-residual disease (MRD), the cytotoxic efficacy of&#xD;
           clofarabine compared with high-dose cytarabine in combination with pegaspargase in these&#xD;
           patients. (Phase III)&#xD;
&#xD;
        -  To compare the incidence of infectious complications after the administration of&#xD;
           daunorubicin hydrochloride versus doxorubicin hydrochloride during reinduction.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To compare the safety profiles of clofarabine and pegaspargase versus high-dose&#xD;
           cytarabine and pegaspargase in these patients.&#xD;
&#xD;
        -  To compare, in terms of MRD, the efficacy of clofarabine and pegaspargase and high-dose&#xD;
           cytarabine and pegaspargase, respectively, versus methotrexate, cyclophosphamide, and&#xD;
           asparaginase in study GER-COALL-07-03, the historical control group (retrospective&#xD;
           comparison).&#xD;
&#xD;
        -  To determine the influence of MRD-based stratification in COALL-09 on overall survival&#xD;
           and event-free survival in a historical comparison of previous COALL studies.&#xD;
&#xD;
      OUTLINE: This is a multicenter, sequential phase II/III study. Patients are stratified to low&#xD;
      risk (LR) or high risk (HR) depending on peripheral white blood cell count on diagnosis, age&#xD;
      on diagnosis, and immunological subtype. Patients undergo 2 randomizations (1 during&#xD;
      intensification and 1 during reinduction) in the study.&#xD;
&#xD;
        -  Preliminary treatment: All patients receive daunorubicin hydrochloride IV over 24 hours&#xD;
           on day -7 and methotrexate intrathecally (IT) once on day -9, -8, or -7.&#xD;
&#xD;
        -  Induction: All patients receive vincristine IV on days 1, 8, 15, and 22; daunorubicin&#xD;
           hydrochloride IV over 24 hours on days 1, 8, and 15; and oral prednisone 3-4 times daily&#xD;
           on days 1-28.&#xD;
&#xD;
      Patients are assessed for minimal-residual disease (MRD) status after induction phase.&#xD;
      Patients not in remission on day 29 are treated off study. Patients with LR disease are&#xD;
      further stratified to LR-reduced (LR-R), LR-standard (LR-S), and LR-intensified (LR-I)&#xD;
      groups; patients with HR disease are further stratified to HR-reduced (HR-R), HR-standard&#xD;
      (HR-S), and HR-intensified (HR-I) groups. Patients in the LR-R and HR-R groups do not undergo&#xD;
      randomization during study.&#xD;
&#xD;
        -  Intensification (randomization 1): Patients receive therapy according to risk and&#xD;
           disease subtypes. Some patients in different risk group are randomized* to receive&#xD;
           high-dose (HD) cytarabine and pegaspargase or clofarabine and pegaspargase.&#xD;
&#xD;
             -  LR-R and LR-S: Patients receive medium-high-dose (mHD) methotrexate IV over 24&#xD;
                hours on days 50, 64, and 78; etoposide phosphate IV over 1-2 hours and cytarabine&#xD;
                IV over 1 hour on day 66; oral mercaptopurine on days 50-56 and 78-120; oral&#xD;
                thioguanine on days 64-70; and methotrexate IT on days 29, 50, 64, and 78. Patients&#xD;
                in LR-S group who still have a detectable MRD load on day 29 are randomized&#xD;
                (randomization 1) to 1 of 2 arms to receive cytarabine and pegaspargase vs.&#xD;
                clofarabine and pegaspargase.&#xD;
&#xD;
                  -  Arm I (cytarabine and pegaspargase) Patients receive HD cytarabine IV over 3&#xD;
                     hours twice daily on days 29-31 and pegaspargase IV over 2 hours on days 31,&#xD;
                     52, and 80.&#xD;
&#xD;
                  -  Arm II (clofarabine and pegaspargase) Patients receive clofarabine IV over 2&#xD;
                     hours on days 29-33 and pegaspargase IV over 2 hours on days 33, 52, and 80.&#xD;
&#xD;
             -  LR-I and precursor B-cell acute lymphoblastic leukemia (ALL) HR-S and HR-I:&#xD;
                Patients receive cyclophosphamide IV over 30 minutes on days 50 and 64; mHD IV over&#xD;
                24 hours on days 51, 65, 78, and 92; etoposide phosphate IV over 1-2 hours and&#xD;
                cytarabine IV over 1 hour on days 80 and 94; oral mercaptopurine on days 64-70 and&#xD;
                92-98; oral thioguanine on days 78-84; and methotrexate IT on days 29, 51, 65, 78,&#xD;
                and 92. All precursor B-cell ALL patients with a detectable MRD load on day 29 and&#xD;
                T-cell ALL patients with an MRD load ≥ 10³ on day 29 are randomized* (randomization&#xD;
                1) to 1 of 2 arms to receive cytarabine and pegaspargase vs. clofarabine and&#xD;
                pegaspargase.&#xD;
&#xD;
                  -  Arm I (cytarabine and pegaspargase) Patients receive HD cytarabine IV over 3&#xD;
                     hours twice daily on days 29-31 and 106-108 and pegaspargase IV over 2 hours&#xD;
                     on days 31, 53, 67, and 108.&#xD;
&#xD;
                  -  Arm II (clofarabine and pegaspargase) Patients receive clofarabine* IV over 2&#xD;
                     hours on days 29-33 and pegaspargase IV over 2 hours on days 33, 53, 67, and&#xD;
                     108.&#xD;
&#xD;
             -  NOTE: *In phase II, all patients with an MRD load of ≥ 104 (on day 29) receive&#xD;
                clofarabine and pegaspargase without randomization.&#xD;
&#xD;
             -  T-cell ALL HR (HR-R, HR-S, and HR-I): Patients receive cyclophosphamide IV over 30&#xD;
                minutes on days 29 and 64; mHD methotrexate IV over 24 hours on days 30, 65, 78,&#xD;
                and 92; etoposide phosphate IV over 1-2 hours and cytarabine IV over 1 hour on days&#xD;
                80 and 94; oral mercaptopurine on days 64-70 and 92-98; oral thioguanine on days&#xD;
                78-84; and methotrexate IT on days 30, 43, 65, 78, and 92. Patients in HR-S and&#xD;
                HR-I group are randomized* (randomization 1) to 1 of 2 arms to receive cytarabine&#xD;
                and pegaspargase vs. clofarabine and pegaspargase.&#xD;
&#xD;
                  -  Arm I (cytarabine and pegaspargase): Patients receive HD cytarabine IV over 3&#xD;
                     hours twice daily on days 43-45 and 106-108 and pegaspargase IV over 2 hours&#xD;
                     on days 32, 45, 67, and 108.&#xD;
&#xD;
                  -  Arm II (clofarabine and pegaspargase): Patients receive clofarabine IV over 2&#xD;
                     hours on days 43-47 and pegaspargase IV over 2 hours on days 32, 47, 67, and&#xD;
                     108.&#xD;
&#xD;
      Patients in HR-I group also receive amsacrine IV over 4 hours and etoposide phosphate IV over&#xD;
      2 hours on days 127 and 128, methylprednisolone IV over 30 minutes on days 127-130, and&#xD;
      methotrexate IT on day 127, at the end of intensification.&#xD;
&#xD;
      NOTE: *In phase II, all patients with an MRD load of ≥ 103 (on day 43) receive clofarabine&#xD;
      and pegaspargase without randomization.&#xD;
&#xD;
        -  CNS therapy: All patients with initial CNS involvement undergo cranial radiotherapy for&#xD;
           a total of 12 or 18 Gy. HR patients (precursor B-cell ALL with initial WBC count ≥&#xD;
           200/nL and T-cell ALL with initial WBC count ≥ 100/nL) with no initial CNS involvement&#xD;
           also undergo cranial radiotherapy for a total of 12 Gy, beginning 2-3 weeks after the&#xD;
           last dose of HD cytarabine or clofarabine. LR patients and HR patients (precursor B-cell&#xD;
           ALL with initial WBC count &lt; 200/nL and T-cell ALL with initial WBC count &lt; 100/nL) with&#xD;
           no initial CNS involvement do not receive initial cranial radiotherapy. At the beginning&#xD;
           of CNS therapy, before cranial radiotherapy, HR-I patients receive vincristine IV on day&#xD;
           1; doxorubicin hydrochloride IV over 24 hours on day 1; oral dexamethasone 3 times daily&#xD;
           on days 1-7; and pegaspargase IV over 2 hours on day 7.&#xD;
&#xD;
      All patients receive interim therapy comprising 3 doses (2 in week 1 and 1 in week 3) of&#xD;
      methotrexate IT and oral mercaptopurine daily during the 4 weeks between intensification and&#xD;
      reinduction.&#xD;
&#xD;
        -  Reinduction (randomization 2): Patients undergo reinduction immediately after completion&#xD;
           of interim therapy. Patients in LR-S, LR-I, HR-S, and HR-I groups are randomized to 1 of&#xD;
           2 arms (doxorubicin hydrochloride vs. daunorubicin hydrochloride)&#xD;
&#xD;
             -  LR-S: Patients receive vincristine IV on days 1 and 8, oral dexamethasone on days&#xD;
                1-14, pegaspargase IV over 2 hours on day 9, cyclophosphamide IV over 30 minutes on&#xD;
                day 22, cytarabine IV or intramuscularly (IM) on days 23-26, oral thioguanine on&#xD;
                days 22-28, and methotrexate IT on days 1, 22, and 36.&#xD;
&#xD;
                  -  Arm III (doxorubicin hydrochloride) Patients receive doxorubicin hydrochloride&#xD;
                     IV over 24 hours on days 1 and 8.&#xD;
&#xD;
                  -  Arm IV (daunorubicin hydrochloride): Patients receive daunorubicin&#xD;
                     hydrochloride IV over 24 hours on days 1 and 8.&#xD;
&#xD;
             -  LR-R and HR-R: Patients are not randomized. They receive vincristine IV on days 1&#xD;
                and 8, oral dexamethasone on days 1-14, pegaspargase IV over 2 hours on day 8, and&#xD;
                methotrexate IT on days 1 and 15.&#xD;
&#xD;
             -  LR-I, HR-S, and HR-I: Patients receive vincristine IV on days 1, 8, 22, and 29;&#xD;
                oral dexamethasone twice daily on days 1-14 and 22-35; cyclophosphamide IV over 30&#xD;
                minutes on days 43 and 57; cytarabine IV or IM on days 43-46 and 57-60; oral&#xD;
                thioguanine on days 43-49 and 57-63; and methotrexate IT* on days 1, 22, and 43.&#xD;
&#xD;
                  -  Arm III (doxorubicin hydrochloride) Patients receive doxorubicin hydrochloride&#xD;
                     IV over 24 hours on days 1, 8, 22, and 29.&#xD;
&#xD;
                  -  Arm IV (daunorubicin hydrochloride) Patients receive daunorubicin&#xD;
                     hydrochloride IV over 24 hours on days 1, 8, 22, and 29.&#xD;
&#xD;
      NOTE: *Patients who underwent cranial radiotherapy do not receive methotrexate IT.&#xD;
&#xD;
        -  Maintenance: Beginning 2-3 weeks after reinduction, all patients receive oral&#xD;
           mercaptopurine daily and oral methotrexate weekly for 2 years. Except for LR-R and HR-R,&#xD;
           patients also receive pegaspargase IV over 2 hours every 3 weeks for 3 doses. Patients&#xD;
           who have not undergone CNS radiotherapy receive methotrexate IT at 3, 6, and 9 months.&#xD;
&#xD;
      Blood and bone marrow samples may be collected periodically for research studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed monthly for 1 year, every 3 months&#xD;
      for 2 years, every 6 months for 2 years, and then annually for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 41 high-risk patients will be accrued for phase II, 296&#xD;
      patients for the first randomization (phase III), and 396 patients for the second&#xD;
      randomization will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and efficacy of clofarabine combined with pegaspargase (phase II)</measure>
    <time_frame>at day 21 after chemotherapy</time_frame>
    <description>minimal residual disease diagnostic, toxicity form</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of infectious complications after administration of daunorubicin hydrochloride vs doxorubicin hydrochloride</measure>
    <time_frame>at the end of reinduction therapy</time_frame>
    <description>toxicity form</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">745</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm I intensification (cytarabine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LR-S patients receive HD cytarabine IV 4 x 3 g over 12 hours daily on days 29-31 and pegaspargase IV over 2 hours on days 31, 52, and 80.&#xD;
LR-I and precursor B-cell ALL HR-S and HR-I patients receive HD cytarabine IV 2.500 over 3 hours twice daily on days 29-31 and 106-108 and pegaspargase IV over 2 hours on days 31, 53, 67, and 108.&#xD;
Followed by standard consolidation therapy regarding to stratification containing:&#xD;
methotrexate, cyclophosphamide, thioguanin, mercaptopurine, etoposide phosphate, amsacrine, cytarabine, methylprednisolone, dexamethasone, vincristine sulfate; whole-brain radiation therapy only if indicated in patients with cns involvement or T-cell ALL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II intensification (clofarabine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LR-S patients receive clofarabine* IV 5 x 40 mg over 2 hours every day on days 29-33 and pegaspargase IV over 2 hours on days 33, 52, and 80.&#xD;
LR-I and precursor B-cell ALL HR-S and HR-I patients receive clofarabine* IV over 2 hours on days 29-33 and pegaspargase IV over 2 hours on days 33, 53, 67, and 108.&#xD;
Followed by standard consolidation therapy regarding to stratification containing:&#xD;
methotrexate, cyclophosphamide, thioguanin, mercaptopurine, etoposide phosphate, amsacrine, cytarabine, methylprednisolone, dexamethasone, vincristine sulfate; whole-brain radiation therapy only if indicated in patients with cns involvement or T-cell ALL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III reinduct.(doxorubicin hydrochl.)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LR-S patients receive doxorubicin hydrochloride IV 30 mg/m2 over 24 hours on days 1 and 8.&#xD;
LR-I, HR-S and HR-I Patients receive doxorubicin hydrochloride IV 30 mg/m2 over 24 hours on days 1, 8, 22, and 29.&#xD;
Followed by standard reinduction and maintenance therapy containing:&#xD;
cyclophophamide, cytarabine, thioguanine, mercaptopurine, methotrexate and pegaspargase, dexamethasone, vincristine sulfate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV reinduct.(daunorubicin hydrochl.)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LR-S patients receive daunorubicin hydrochloride IV 36 mg/m2 over 24 hours on days 1 and 8.&#xD;
LR-I, HR-S and HR-I Patients receive daunorubicin hydrochloride IV 36 mg/m2 over 24 hours on days 1, 8, 22, and 29.&#xD;
Followed by standard reinduction and maintenance therapy containing:&#xD;
cyclophophamide, cytarabine, thioguanine, mercaptopurine, methotrexate and pegaspargase, dexamethasone, vincristine sulfate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amsacrine</intervention_name>
    <description>one block amsacrine together with etoposide and methylprednisolone for very high risk patients</description>
    <arm_group_label>Arm I intensification (cytarabine)</arm_group_label>
    <arm_group_label>Arm II intensification (clofarabine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>one block clofarabine with Asparaginase for MRD positive patients after induction</description>
    <arm_group_label>Arm II intensification (clofarabine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>together wit MTX and ASP in consolidation and together with cytarabine and 6-TG in reinduction</description>
    <arm_group_label>Arm I intensification (cytarabine)</arm_group_label>
    <arm_group_label>Arm II intensification (clofarabine)</arm_group_label>
    <arm_group_label>Arm III reinduct.(doxorubicin hydrochl.)</arm_group_label>
    <arm_group_label>Arm IV reinduct.(daunorubicin hydrochl.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>part of different chemotherapy blocks in consolidation and reinduction</description>
    <arm_group_label>Arm I intensification (cytarabine)</arm_group_label>
    <arm_group_label>Arm III reinduct.(doxorubicin hydrochl.)</arm_group_label>
    <arm_group_label>Arm IV reinduct.(daunorubicin hydrochl.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin hydrochloride</intervention_name>
    <description>part of induction and reinduction therapy</description>
    <arm_group_label>Arm II intensification (clofarabine)</arm_group_label>
    <arm_group_label>Arm IV reinduct.(daunorubicin hydrochl.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>part of reinduction therapy</description>
    <arm_group_label>Arm I intensification (cytarabine)</arm_group_label>
    <arm_group_label>Arm II intensification (clofarabine)</arm_group_label>
    <arm_group_label>Arm III reinduct.(doxorubicin hydrochl.)</arm_group_label>
    <arm_group_label>Arm IV reinduct.(daunorubicin hydrochl.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin hydrochloride</intervention_name>
    <description>part of reinduction therapy</description>
    <arm_group_label>Arm III reinduct.(doxorubicin hydrochl.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide phosphate</intervention_name>
    <description>part of different chemotherapy blocks</description>
    <arm_group_label>Arm I intensification (cytarabine)</arm_group_label>
    <arm_group_label>Arm II intensification (clofarabine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <description>part of different chemotherapy blocks</description>
    <arm_group_label>Arm III reinduct.(doxorubicin hydrochl.)</arm_group_label>
    <arm_group_label>Arm IV reinduct.(daunorubicin hydrochl.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>part of different chemotherapy blocks</description>
    <arm_group_label>Arm I intensification (cytarabine)</arm_group_label>
    <arm_group_label>Arm II intensification (clofarabine)</arm_group_label>
    <arm_group_label>Arm III reinduct.(doxorubicin hydrochl.)</arm_group_label>
    <arm_group_label>Arm IV reinduct.(daunorubicin hydrochl.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>part of different chemotherapy blocks</description>
    <arm_group_label>Arm I intensification (cytarabine)</arm_group_label>
    <arm_group_label>Arm II intensification (clofarabine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegaspargase</intervention_name>
    <description>part of different chemotherapy blocks</description>
    <arm_group_label>Arm I intensification (cytarabine)</arm_group_label>
    <arm_group_label>Arm II intensification (clofarabine)</arm_group_label>
    <arm_group_label>Arm III reinduct.(doxorubicin hydrochl.)</arm_group_label>
    <arm_group_label>Arm IV reinduct.(daunorubicin hydrochl.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thioguanine</intervention_name>
    <description>part of different chemotherapy blocks</description>
    <arm_group_label>Arm I intensification (cytarabine)</arm_group_label>
    <arm_group_label>Arm II intensification (clofarabine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine sulfate</intervention_name>
    <description>part of intravenous chemotherapy</description>
    <arm_group_label>Arm I intensification (cytarabine)</arm_group_label>
    <arm_group_label>Arm II intensification (clofarabine)</arm_group_label>
    <arm_group_label>Arm III reinduct.(doxorubicin hydrochl.)</arm_group_label>
    <arm_group_label>Arm IV reinduct.(daunorubicin hydrochl.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Whole-brain radiation therapy</intervention_name>
    <description>patients with initial cns involvement receive cranial irradiation</description>
    <arm_group_label>Arm I intensification (cytarabine)</arm_group_label>
    <arm_group_label>Arm II intensification (clofarabine)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        diagnosis after the first and before the 18th birthday AND confirmed diagnosis of acute&#xD;
        B-precursor or or T-cell leukemia AND parents or guardians/patients give consent for&#xD;
        inclusion in the study and transmission of data AND if none of exclusion criteria is&#xD;
        accomplished&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        BCR/ABL rearrangement positive OR prior cytostatic treatment lasting &gt; 7 days or prior&#xD;
        treatment with cytostatic drugs other than vincristine, daunorubicin and prednisone OR&#xD;
        prior severe illnesses which make treatment per the protocol impossible from the outset&#xD;
        (BUT trisomy 21 is not an exclusion criterion) OR absence of the baseline data required for&#xD;
        assignment to a risk group in accordance with the protocol (BUT patients for whom the MRD&#xD;
        value could not be determined for technical reasons will be treated as protocol patients)&#xD;
        OR the disease is a secondary malignancy or relapse OR death before the start of treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Horstmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenanstalten Gilead gCmbH Neurochirurgische Klinik</name>
      <address>
        <city>Bielefeld</city>
        <zip>33617</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte</name>
      <address>
        <city>Bremen</city>
        <zip>D-28205</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <zip>D-40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik Fuer Kinder-und Jugendmedizin - Universitaetsklinikum Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17487</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg - Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Bone Marrow Transplantation and Hematology and Oncology</name>
      <address>
        <city>Idar-Oberstein</city>
        <zip>D-55743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Krefeld GmbH</name>
      <address>
        <city>Krefeld</city>
        <zip>D-47805</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets - Kinderklinik</name>
      <address>
        <city>Leipzig</city>
        <zip>D-04317</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg University</name>
      <address>
        <city>Mainz</city>
        <zip>D-55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. von Haunersches Kinderspital der Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Krankenhaus Muenchen - Harlaching</name>
      <address>
        <city>Munich</city>
        <zip>D-81545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik St. Hedwig-Kinderklinik</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Horst-Schmidt-Kliniken</name>
      <address>
        <city>Wiesbaden</city>
        <zip>D-65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Kliniken Wuppertal University Hospital</name>
      <address>
        <city>Wuppertal</city>
        <zip>D-42283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.kinderkrebsinfo.de/health_professionals/clinical_trials/pohkinderkrebsinfotherapiestudien/coall_08_09/index_eng.html</url>
    <description>Clinical trial summary from the information portal of the German Society of Paediatric Oncology and Haematology (GPOH)</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 23, 2010</study_first_submitted>
  <study_first_submitted_qc>October 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2010</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>childhood acute lymphoblastic leukemia</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Amsacrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

